Skip to content
Class Notes

Comprehensive Guide to Addiction Medications and T

This detailed chart outlines key addiction medications, their indications, neurotransmitter targets, side effects, dosing, and special considerations for age, pregnancy, and breastfeeding in the treatment of opioid and alcohol dependence.

Preview 2 of 5 pages

See the first 2 pages exactly as they appear in the document.

  1. Page 1
    Read page 1 as text

    Addiction Medications Table Week B CH O W Bl. M N H M V n t M T V “HIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 5 MEDICATION TABLE DROPBOX BY SUNDAY AT 11 59 P.M. MT. Drug Name Indication Neurotransmitterfs) Affected Target Symptoms Half-life (Tl'2), Metabolism (CYP 450 enzyme) Notable Side Effects (link to NT or affected brain circuit) Initial Dosing Considerations Specific lifespan considerations (age, pregnancy, breastfeeding) Buprenorphine (Subutex) Indication: Maintenance treatment of opioid dependence Maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to moderate doses of a trans mucosal buprenorphine containing product Moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal 24-42 hours CYP450: CYP3A4 24-42 hours CYP450: CYP3A4 Half-life: 24-42 hours CYP450: CYP3A4 Headache, constipation, nausea Oral hypoesthesia, glosscdynia Orthostatic hypotension Respiratory distress Hepatotoxicity Binds to mu opioid receptors Initial dosing: Sublingual 8-32 mg day Controlled studies have not been conducted in pregnant women. Buprenorphine may be preferable to methadone in pregnant women. Neonatal opioid withdrawal syndrome has been reported following use of Buprenorphine during pregnancy Some drag is buprenorphine containing product, followed by dose adjustment for a minimum of 7 days Neurotransmitter affected: Mu opioid receptor partial agonist Antagonist at the kappa opioid receptor Target symptoms: Opioid dependence found in mother's breast milk. Recommended either to discontinued drug or formula feed. Use with caution in elderly. Some patients may tolerate lower doses better. Buprenorphine Naloxone (Suboxone, Zubsolv, Bunavail) Indication: Treatment, and maintenance of opioid dependence. Induction of treatment for opioid dependence Maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to moderate Suboxone: 24-42 hours Naloxone: 2-12 hours CYP450: CYP3A4 Headache, constipation, nausea, oral hypcesthesia, glosscdynia, orthostatic hypotension, sedation Binding at mu opioid receptors Initial dosing: Bunavail: Day 1: induction dose: Initial: Buccal: Buprenorphine 2.1 mg naloxone 0.3 mg ; may repeat dose after 2 hours, based on control of acute withdrawal symptoms; maximum total dose: buprenorphine 4.2 mg naloxone 0.7 mg. Day 2:

  2. Page 2
    Read page 2 as text

    doses of a trans mucosal Neurotransmitters: Antagonist at the kappa opioid receptor Mu opioid receptor partial agonist Target symptoms: Opioid dependence induction dose: Up to buprenorphine 8.4 mg naloxone 1.4 mg as a single dose Suboxone: Day 1: induction dose: Initial: Sublingual: Buprenorphine 2 mg naloxone 0.5 mg or buprenorphine 4 mg naloxone 1 mg; may titrate dose, based on control of acute withdrawal symptoms, in buprenorphine 2 mg naloxone 0.5 mg or buprenorphine 4 mg naloxone 1 mg increments approximately every 2 hours up to a total dose of buprenorphine 8 mg naloxone 2 mg. Day 2: induction dose: Sublingual: Up to buprenorphine 16 mg naloxone 4 mg as a single dose. Zubsolv: Day 1: induction dose: Sublingual: Stan with an initial dose of buprenorphine 1.4 mg naloxone C.36 mg; based on control of acute withdrawal symptoms, may administer additional doses in increments of 1 to 2 buprenorphine 1.4 mg naloxone C.36 mg tablets every 1.5 to 2 hours to a total day 1 dose up to buprenorphine 5.7 mg naloxone 1.4 mg. Some patients (eg, those with recent exposure to buprenorphine) may tolerate up to buprenorphine 4.2 mg naloxone 1.08 mg as a single,

3 more pages in the full document

Unlock it once and it stays in your library, ready to chat with or turn into flashcards.

Unlock the full document

More Pharmacology study materials

See all

Study this document with CramX

Once it is in your library, every tool can work from it.